CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$45.71 USD
+0.13 (0.29%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $45.71 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$45.71 USD
+0.13 (0.29%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $45.71 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $57.96, marking a -1.29% move from the previous day.
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
by Zacks Equity Research
bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
by Zacks Equity Research
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
Charles River (CRL) Forges Collaboration With Ship of Theseus
by Zacks Equity Research
Charles River (CRL) is set to perform plasmid production for Ship of Theseus.
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $65.19, marking a +1.72% move from the previous day.
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $65.06, signifying a +0.71% move from its prior day's close.
Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development
by Zacks Equity Research
Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
by Zacks Equity Research
bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reachead $71.08 at the closing of the latest trading day, reflecting a -0.74% change compared to its last close.
Vertex (VRTX) Continues to Diversify Beyond CF Franchise
by Zacks Equity Research
While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month.
CRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $71.96, marking a +0.69% move from the previous day.
bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up
by Zacks Equity Research
bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.
CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up
by Zacks Equity Research
CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.
Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Amphastar's (AMPH) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its pharmaceutical products.
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.
Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Altimmune's (ALT) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the development of its lead pipeline candidate, pemvidutide.
CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Vericel Corporation (VCEL) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates
by Zacks Equity Research
Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR's (CRSP) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the launch activities of the newly approved gene therapy, Casgevy (exa-cel).
Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders
by Zacks Equity Research
Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for treatment.
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $70.01, moving +1.71% from the previous trading session.